Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
DOJ Opens Criminal Investigation Into E. Jean Carroll Over Alleged Perjury 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
New World Screwworm Found Near U.S. Border Raises Threat to Cattle Industry and Beef Prices 
J.P. Morgan Sees Major Upside for Prysmian as Optical Fiber Prices Surge 
US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns 
Brazil Struggles to Stop Illegal Amazon Gold Mining as Gold Prices Surge 
SEC Tokenized Stock Approval Still Expected as Regulatory Framework Advances 
Apollo Ends Pursuit of Bodycote, Withdraws £1.52 Billion Takeover Proposal 
US Sanctions M23 and FDLR Commanders Amid Ongoing Eastern Congo Conflict 
Trump Forced Labour Tariff Plan Faces Criticism as Experts Question Effectiveness 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Alaska Air Group Eyes Return of Financial Guidance as Fuel Market Volatility Eases 
Apple Unveils Enhanced Apple Intelligence and Next-Generation Siri at WWDC 2026 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, branded as Nereus, marking the first new FDA-approved treatment for motion-induced vomiting in more than 40 years. The company announced that it plans to launch the drug in the United States in the coming months, a move that could significantly change the treatment landscape for motion sickness.
Motion-induced vomiting, often referred to as motion sickness, occurs when the brain receives conflicting signals from the eyes, inner ear, and body sensors. This condition commonly affects people during travel activities such as boating, driving, or flying and has long relied on older treatment options with limited innovation.
The FDA’s approval of Nereus was supported by two late-stage clinical trials involving a total of 681 patients. Results from these studies showed that tradipitant significantly reduced episodes of vomiting compared to placebo. The drug works by blocking a specific brain receptor associated with nausea and vomiting, offering a targeted and modern approach to treatment.
According to H.C. Wainwright analyst Raghuram Selvaraju, peak annual sales of tradipitant for motion sickness alone could exceed $100 million in the U.S., highlighting its strong commercial potential. Currently available motion sickness treatments include Viatris’ scopolamine patch Transderm Scop, WellSpring Pharmaceutical’s Bonine, and Prestige Consumer Healthcare’s Dramamine, many of which have been on the market for decades.
Tradipitant’s regulatory journey faced challenges in the past. In December 2018, the FDA placed a partial clinical hold on the drug, requesting additional long-term toxicity studies in dogs after classifying motion sickness as a chronic condition. However, the agency reversed its stance, reclassifying motion sickness as an acute condition and lifting the clinical hold on December 4, eliminating the need for further studies.
Vanda licensed tradipitant from Eli Lilly in 2012 and continues to study the drug for multiple indications, including gastroparesis and nausea linked to certain diabetes medications. The company has not yet disclosed pricing details for Nereus.
